The Hidden Costs of Penicillin Allergy Labels

Penicillin allergy is one of the most frequently reported drug allergies in the world—but in most cases, it’s incorrect. While the clinical consequences of mislabeling are well documented, a less visible yet equally pressing issue is its economic impact. A study published in The American Journal of Managed Care underscores how false penicillin allergy labels quietly inflate healthcare costs and burden patients, hospitals, and public health systems alike.

The financial footprint of a false allergy

Patients labeled as allergic to penicillin are far more likely to be prescribed alternative antibiotics that are broader-spectrum, less effective, or more expensive. This shift in prescribing behavior leads to increased pharmacy costs, longer hospital stays and more complex and costly treatments. In Europe alone, an estimated 118 million people are prescribed antibiotics each year, consuming over 2.8 billion doses. When an allergy to penicillin is incorrectly recorded, patients are often switched from standard treatments —a low-cost, effective option—to second-line alternatives (not always available), which can cost up to 100 times more per dose. These mislabelings are not only clinically inefficient, but they contribute to an estimated €2 billion annual burden across European healthcare systems—equivalent to about 1.06% of the EU’s 2024 total budget.

Antibiotic resistance: a costly consequence

The overuse of broad-spectrum antibiotics doesn’t just affect individual patients. It has system-wide consequences, including the rise of antibiotic-resistant organisms, which are harder and more expensive to treat. In fact, studies show that patients with a reported penicillin allergy are:

• 9 times more likely to receive broad-spectrum antibiotics
• 50% more likely to develop antibiotic-resistant infections

This not only drives up treatment costs but fuels the global antimicrobial resistance (AMR) crisis, contributing to the emergence of superbugs—organisms for which there are few, if any, treatment options left. Alarmingly, this situation is exacerbated by the lack of incentives for pharmaceutical companies to develop new antibiotics, making accurate diagnosis more urgent than ever.

A low-cost solution with high impact

The good news? Many of these costs are avoidable. At Bioherent, we believe that a correct diagnosis is not just a clinical responsibility—it’s a financial and public health imperative. That’s why we are developing accurate, accesible and fast in vitro tools to support better allergy diagnostics. Through innovations in biosensing, nanotechnology, and immunochemistry, we aim to reduce misdiagnosis and its downstream costs, helping health systems treat patients accurately and sustainably.

Reference:

Blumenthal, K.G., Ryan, E.E., Li, Y., Lee, H., Kuhlen, J.L., Shenoy, E.S., & Banerji, A. (2020). The Economic Burden of Penicillin Allergy Evaluation. The American Journal of Managed Care, 26(4), e107–e113. https://doi.org/10.37765/ajmc.2020.42316